Nanomedical Drug Delivery for Neurodegenerative Diseases, 2022, Pages 17-39
This book chapter advances SDG #3 and #10 by presenting drug delivery systems based on nanotechnology to treat Alzheimer’s disease.
Nanomedical Drug Delivery for Neurodegenerative Diseases, 2022, Pages 223-242
This book chapter advances SDG #3 and #10 by highlighting a few newly updated nano drug delivery technologies implemented in Alzheimer’s disease therapies and prospects for the future regarding potential molecular mechanisms of nano drug delivery methods
An article on comorbid dementia and depression, in the context of SDG 3, focusing specifically on the effectiveness of music interventions on depressive symptoms for people with dementia.
This Article supports SDGs 3 and 5, focusing on the association between testosterone concentrations and risk of major adverse cardiac events in older women.
This book chapter advances SDG 3 and 10 by presenting that (1) some of these depression scales do not correlate, suggesting that they assess different aspects of depression; (2) reports of depression in dementia vary based on depression in dementia scale used; and (3) severe memory impairment may impact the ability to assess depression in the patients using self-reports.
This book chapter advances SDG #3 and #10 by reviewing studies that showed treatments with multiple sessions of rTMS can influence cognition in people with neurodegenerative diseases. The chapter also considers novel therapeutic approaches based on the clinical use of rTMS.
Background: Menstrual health is essential for gender equality and achieving the sustainable development goals. Though currently lacking, understanding and addressing menstrual health and social related inequalities requires comparison of experiences between menstruators with and without disabilities. Methods: We completed a mixed-methods population-based study of water, sanitation and hygiene, disability and menstrual health in TORBA and SANMA Provinces, Vanuatu.
Background: Hepatitis C elimination may be possible with broad uptake of direct-acting antiviral treatments (DAAs). In 2016 the Australian government committed A$1.2 billion for five years of unlimited DAAs (March 2016 to February 2021) in a risk-sharing agreement with pharmaceutical companies. We assess the impact, cost-effectiveness and net economic benefits likely to be realised from this investment.
This article examines whether seasonality and rainfall predict reported syndromes associated with leptospirosis, typhoid and dengue in Fiji.
